Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. - Wikidata - wikimedia - TriplyDB

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

http://www.wikidata.org/entity/Q35594723

about

Hepatitis C virus and type 2 diabetes Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?Managing chronic hepatitis C in the difficult-to-treat patient Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3 Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies Mechanisms and significance of liver steatosis in hepatitis C virus infection Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease Treatment of hepatitis C virus infection Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome.Evolution of interferon-based therapy for chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.Central portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C.Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress Non-alcoholic fatty liver: a common manifestation of a metabolic disorder.Steatosis and fibrosis in patients with chronic hepatitis C.Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Management of chronic hepatitis C virus infection: a new era of disease control.Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice.Hepatitis C virus infection and nonalcoholic steatohepatitis Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link.Hepatitis C and steatosis: a reappraisal.Hepatitis C virus (HCV) infection and hepatic steatosis The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.Electron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats.Histological assessment of non-alcoholic fatty liver disease.Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand.Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.Liver disease in injection drug users with hepatitis C, with and without HIV coinfection.Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.Role of viral and host factors in interferon based therapy of hepatitis C virus infection

P2860

Q24658049-ACE86D36-881E-4FF1-B2A7-BDE48D7E3A13 Q26752583-C14C7146-073E-4EC7-ABB6-FF11A4420A9F Q27478329-F4418633-1B3C-4337-A6DD-95312B2B06C7 Q27490409-AA9B9E22-2904-4C86-9AAD-5347A13CAFFD Q28072762-F4E29A3F-6C6A-454B-8A7F-5C9EFFCB4E74 Q28729225-BE38E0D6-5103-45F5-AF7F-9EC077FFC129 Q30417045-4F187FC7-62A3-45E9-A702-1E34557094BC Q30453975-62C24C7B-6A42-4387-9492-350422390536 Q30485410-45766D0E-5D01-4837-86FB-E90000754AAC Q33866272-FE9A0B36-7D2F-475C-86BB-2016F4F69A0C Q33909796-6CDF4C5D-D13C-4F9E-95A0-6D33E2A90226 Q34099424-715A431F-16D1-4F4C-A31C-9C5F82B196A3 Q34225234-A168B2AD-2DBE-4E39-90DE-ED731716F7A1 Q34342092-E7C553B5-11F8-4B25-872C-3D6B231EEECA Q34409039-02D6385B-F9B4-4CBE-9B6F-760D6C522896 Q34698082-0D6EA592-8C07-4107-9E85-5BD34A601223 Q35007172-DF8A81CB-618C-46B7-9B2A-FD3C6F9D2A13 Q35259669-51876275-6352-4F8B-804B-4B82A63C21DE Q35538766-B78DD783-6006-4780-81FA-F177D7DB9596 Q35587506-C9908460-C96D-485A-8C12-EFBDDB11D4AA Q35596306-849402D5-AFB7-4F0D-8460-04BC93919AA3 Q35596325-932EB220-228B-49F5-A609-813265BCC010 Q35823410-8232D899-5ECE-4E52-9AB4-99219FE36130 Q35884239-A091A012-2F56-431C-B370-F6833336715E Q36179898-AEE316D0-F7D3-4D54-8334-0340716EB077 Q36286323-23B0A45A-AF47-4244-B085-889131C98926 Q36377276-E691A3CA-5EFE-4A70-80D1-83DEFFC72B92 Q36449231-1B1C0DD3-241A-4B16-BF9F-DF114F009111 Q36457818-BF41D803-C39F-4216-A350-5D420BE9ECEA Q36503299-3EADE4F7-7589-4D47-87D8-804CC2C66A90 Q36528728-055C0D62-078C-4105-8D2B-7A99F04E82AE Q36634377-55CBE453-401D-4F31-802C-1478E4C402D3 Q36672577-0FFC0172-116F-4932-AAB7-1980B25279E5 Q36700770-99D7945D-2AEE-47F7-A47C-5B56768CC0FD Q37115792-3168CF48-1348-41B5-86AF-65531D20222C Q37133483-E8D9390C-EFC9-4F44-ACF0-3AF1B089C822 Q37217299-0DBC94FE-74CA-4CF6-A686-83645ADD795C Q37235533-EF7B1023-0A1E-4A6B-B269-59F57EBA1D85 Q37345868-D6C2E2CF-D83A-40FE-99E8-F11108F3CF5A Q37362240-79E5CB59-304F-4A10-B6A9-91327232C288

P2860

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

http://www.wikidata.org/entity/Q35594723

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Effect of weight reduction on ...... ents with chronic hepatitis C.

@ast

Effect of weight reduction on ...... ents with chronic hepatitis C.

@en

type

label

Effect of weight reduction on ...... ents with chronic hepatitis C.

@ast

Effect of weight reduction on ...... ents with chronic hepatitis C.

@en

prefLabel

Effect of weight reduction on ...... ents with chronic hepatitis C.

@ast

Effect of weight reduction on ...... ents with chronic hepatitis C.

@en

P1433

Q35594723-CE0FC1EA-F23E-48E3-BE6D-6EF0D9D289E7

P1476

Q35594723-E4550FFB-9715-4FB4-8F45-D76948CD1826

P2093

Q35594723-028189BB-0BCC-4FCF-B1A5-025C0D165F40

Q35594723-25D3AF4A-710A-48E1-8275-408D20CAC906

Q35594723-57BACF15-1659-4CA1-9B57-5D69C1330445

Q35594723-C4D9C236-E5FB-45C5-BBEA-5B951B66F2A9

P2860

Q35594723-0248A4F7-E7D0-4666-A477-A3AE7872B3F5

Q35594723-092F5389-D697-4529-900D-BD533BD556B7

Q35594723-0FDF6DE1-A9EB-4D27-89AE-7A21184DEF58

Q35594723-29442F3F-405B-41B0-8EC9-B4C329FDDC17

Q35594723-2ACD79DB-D08A-4E7B-9683-B7F3A1DA7652

Q35594723-2D6DC1AA-C890-471E-93DB-82E3769AF660

Q35594723-31F812B8-EA27-411D-B765-202772AD4C3E

Q35594723-3E09DC57-8C45-4BBD-8B4D-B73931FB3D7D

Q35594723-49C1619E-D73B-451E-8441-535B0BC9E6F9

Q35594723-4A8BE3FF-7E57-4D6D-B543-914B65AF544F

P304

Q35594723-DD0B49DC-0F83-4C91-A5C9-6166469A9465

P31

Q35594723-054A9E03-CC71-42F9-8E49-5D2C65273BF4

P356

Q35594723-C96BFD35-0C0C-4006-98F1-776744B02BFC

P407

Q35594723-7B812630-5099-42FA-B6D3-1E19AF1ED6E8

P433

Q35594723-AE13FE79-80B6-4D24-A8B1-032891B27513

P478

Q35594723-0B890857-C202-48BF-BBBD-3D3C330BCA9F

P50

Q35594723-51595F69-04E2-4FE3-B776-C017B00CA799

Q35594723-81B534EA-2AB7-4342-A535-4DA758359ED4

Q35594723-E53F3884-1E17-45BC-888C-C2669773140B

Q35594723-F4AC0EB5-D367-4385-9120-319AAACFAE59

P577

Q35594723-4696AE25-086B-4D4E-A8D6-CAE3BFF4984A

P5875

Q35594723-790B7007-62F2-4E56-9E7F-85F60B473B75

P698

Q35594723-8E82DCCA-9237-45FE-8C59-F8CBC1D9B290

P932

Q35594723-9385DEDF-7EBC-42FE-81E4-1B7D481EFEC2

P356

P1433

P1476

Effect of weight reduction on ...... ients with chronic hepatitis C

@en

P2093

D M Purdie

http://www.w3.org/2001/XMLSchema#string

G A Macdonald

http://www.w3.org/2001/XMLSchema#string

J R Jonsson

http://www.w3.org/2001/XMLSchema#string

S Ash

http://www.w3.org/2001/XMLSchema#string

P2860

Altered alveolar macrophage function in calorie-restricted rats

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production

Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors

Histological grading and staging of chronic hepatitis

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.

Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective.

P304

89-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.51.1.89

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Andrew D. Clouston

Elizabeth Powell

Johannes B. Prins

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11298126

http://www.w3.org/2001/XMLSchema#string

P698

12077098

http://www.w3.org/2001/XMLSchema#string

P932

1773265

http://www.w3.org/2001/XMLSchema#string